Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05813223
EARLY_PHASE1

Effect of Gefapixant on Cough-related Brain Activity in Patients With Chronic Cough

Sponsor: Stuart Mazzone

View on ClinicalTrials.gov

Summary

Recently, a new drug called Gefapixant passed phase III clinical trials for cough suppression in patients with chronic cough. The goal of this clinical trial is to investigate the effect of acute and prolonged administration of the drug Gefapixant on cough-related brain activity in patients with chronic cough. The main question it aims to answer is: does the mechanism of action of Gefapixant on the brainstem and brain circuits regulating cough differ between acute and prolonged therapy in people with chronic cough? Participants have their brain activity and their sensitivity to cough-inducing substances measured as well as complete questionnaires about their cough before and while taking daily Gefapixant.

Official title: The Effect of Acute and Prolonged Administration of Gefapixant on Cough-related Brain Activity in Patients With Chronic Cough

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

31

Start Date

2024-01-01

Completion Date

2026-06-30

Last Updated

2024-05-09

Healthy Volunteers

No

Conditions

Interventions

DRUG

Gefapixant

Purinergic (P2X3) Receptor antagonist. Film-coated tablet taken orally.

Locations (1)

The University of Melbourne

Parkville, Victoria, Australia